Does Macrophage Migration Inhibitory Factor predict the prognosis of COVID-19 disease?
Adult
Aged
Biomarkers
/ blood
COVID-19
/ diagnosis
Comorbidity
Cross-Sectional Studies
Female
Hospitalization
/ statistics & numerical data
Humans
Inflammation
/ blood
Intensive Care Units
/ statistics & numerical data
Intramolecular Oxidoreductases
/ blood
Macrophage Migration-Inhibitory Factors
/ blood
Male
Middle Aged
Prognosis
Qualitative Research
ROC Curve
COVID-19
Inflammation
Macrophage migration
SARS-Cov-2
inhibitory factor
Journal
Journal of infection in developing countries
ISSN: 1972-2680
Titre abrégé: J Infect Dev Ctries
Pays: Italy
ID NLM: 101305410
Informations de publication
Date de publication:
31 Mar 2021
31 Mar 2021
Historique:
received:
25
09
2020
accepted:
11
01
2021
entrez:
11
4
2021
pubmed:
12
4
2021
medline:
24
4
2021
Statut:
epublish
Résumé
The aim of this study is to investigate whether macrophage migration inhibitory factor (MIF) predicts the prognosis of COVID-19 disease. This descriptive and cross-sectional study was conducted on 87 confirmed COVID-19 patients. The patients were separated into two groups according to the admission in the ICU or in the ward. MIF was determined batchwise in plasma obtained as soon as the patients were admitted. Both groups were compared with respect to demographic characteristics, biochemical parameters and prediction of requirement to ICU admission. Forty seven patients in ICU, and 40 patients in ward were included. With respect to MIF levels and biochemical biomarkers, there was a statistically significant difference between the ICU and ward patients (p< 0.024). In terms of ICU requirement, the cut-off value of MIF was detected as 4.705 (AUC:0.633, 95%CI:0.561-0.79, p= 0.037), D-dimer was 789 (AUC:0.779, 95%CI: 0.681-0.877, p= 0.000), troponin was 8.15 (AUC: 0.820, 95%CI:0.729-0.911, p= 0.000), ferritin was 375 (AUC: 0.774, 95%CI:0.671-0.876, p= 0.000), and lactate dehydrogenase (LDH) was 359.5 (AUC:0.843, 95%CI: 0.753-0.933, p= 0.000). According to the logistic regression analysis; when MIF level > 4.705, the patient's requirement to ICU risk was increased to 8.33 (95%CI: 1.73-44.26, p= 0.009) fold. Similarly, elevation of troponin, ferritin and, LDH was shown to predict disease prognosis (p< 0.05). Our study showed that MIF may play a role in inflammatory responses to COVID-19 through induction of pulmonary inflammatory cytokines, suggesting that pharmacotherapeutic approaches targeting MIF may hold promise for the treatment of COVID-19 pneumonia.
Substances chimiques
Biomarkers
0
Macrophage Migration-Inhibitory Factors
0
Intramolecular Oxidoreductases
EC 5.3.-
MIF protein, human
EC 5.3.2.1
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
398-403Informations de copyright
Copyright (c) 2021 Hamad Dheir, Selcuk Yaylaci, Savas Sipahi, Ahmed Cihad Genc, Deniz Cekic, Fatma Betul Tuncer, Erdem Cokluk, Havva Kocayigit, Ahmed Bilal Genc, Salih Salihi, Ceyhun Varim, Oguz Karabay.
Déclaration de conflit d'intérêts
No Conflict of Interest is declared